← Eichor
Condition: Intermediate Risk Prostate Cancer Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Intermediate Risk Prostate Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

The SUGAR Study; SBRT and Relugolix) for Prostate Cancer
Phase 2 · 4 location(s) · Yale University · NCT06111781SRT Versus SRT+ADT in Prostate Cancer
Phase 3 · 1 location(s) · Marco Lorenzo Bonu · NCT05019846The PRECISION Study: 3 Fractions of Prostate SBRT and RayPilot HypoCath Image Guidance
NA · 1 location(s) · NHS Lothian · NCT06117059ABlative Radiotherapy (for) Unfavorable Prostate Tumors 2.0
Phase N/A · 1 location(s) · University of Milano Bicocca · NCT07407608An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05454488Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Ly
NA · 1 location(s) · Ruijin Hospital · NCT07115992Spanish Urological Association Registry of Patients on Active Surveillance
Phase N/A · 1 location(s) · Fundación Instituto Valenciano de Oncología · NCT02865330Androgen-responsive POSLUMA-guided Intra-prostatic Boost
Phase 2 · 4 location(s) · Martin T. King, MD, PhD · NCT07393867Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-I
Phase 2 · 1 location(s) · Weill Medical College of Cornell University · NCT04402151Two-Fraction Ultrahypofractionated Radiotherapy With Focal Boost for Intermediate Risk, Localized Prostate Cancer
NA · 1 location(s) · UMC Utrecht · NCT06518226Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiothe
NA · 20 location(s) · Center Eugene Marquis · NCT03830788ABlative Radiotherapy (for) Unfavorable Prostate Tumors
Phase N/A · 1 location(s) · University of Milano Bicocca · NCT04831983Safety and Efficacy of Two-step Radical Prostatectomy
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT05722392Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
Phase N/A · 1 location(s) · British Columbia Cancer Agency · NCT06200974High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
NA · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT04945642ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
Phase 2 · 1 location(s) · NYU Langone Health · NCT06397703REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)
Phase 2 · 1 location(s) · National Cancer Institute, Naples · NCT07302451Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Phase 2 · 3 location(s) · Regina Elena Cancer Institute · NCT05557604MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate Cancer
NA · 1 location(s) · Mayo Clinic · NCT05438563Feasibility Trial of Single-Dose Radiotherapy for Localized Low and Intermediate Risk Prostate Cancer
NA · 1 location(s) · Branch Office of "Hadassah Medical Ltd" · NCT07112781Image-guided, Tumor-focused Radiotherapy Treatment in Intermediate and High-risk Prostate Cancer
Phase 2 · 1 location(s) · University of California, San Diego · NCT06990542Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Phase 3 · 4 location(s) · Proton Collaborative Group · NCT01492972Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT
NA · 1 location(s) · Fundacao Champalimaud · NCT04035642A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Phase 2 · 7 location(s) · Candel Therapeutics, Inc. · NCT07332000Two-fraction Versus Five-fraction Stereotactic Radiotherapy for Localized Prostate Cancer
NA · 1 location(s) · Rabin Medical Center · NCT06027892High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
NA · 1 location(s) · University of Nebraska · NCT05754580Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate
Phase 2 · 1 location(s) · German Oncology Center, Cyprus · NCT06772441Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
Phase 1 · 9 location(s) · Amgen · NCT06613100Two-fraction Proton Therapy With MRI Guidance for Prostate Cancer: A Phase II Trial
NA · 1 location(s) · Hong Kong Sanatorium & Hospital · NCT07130682Robotic Hemi-Prostatectomy With Urethral Preservation in Low and Intermediate Risk Monolateral Prostate Cancer
NA · 1 location(s) · Fondazione del Piemonte per l'Oncologia · NCT05832736
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.